Filing Flows › Enovis (ENOV) › Q3 2026 › vs Q3 2025
Enovis (ENOV) Q3 2026 vs Q3 2025 (year over year)
Enovis's revenue rose $9.8M (+2%) from $549M in Q3 2025 to $559M in Q3 2026. The biggest changes: Reconstructive +$15.4M (+6%); Prevention & Recovery −$5.5M (-2%). Gross margin 60.8% against 59.9% (+0.9 pts).
Enovis, Q3 2026: revenue $559M (+2% year over year), operating margin 0.6%, net earnings $3.4M, operating cash flow $71.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 60.8% | 59.9% | +0.9 pts |
| Operating margin | 0.6% | -101.7% | +102.3 pts |
| Net margin | 0.6% | -104.0% | +104.6 pts |
| Free cash flow margin | 6.3% | 5.3% | +1.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Prevention & Recovery | $285M | $291M | −$5.5M | -2% |
| Reconstructive | $273M | $258M | $15.4M | +6% |
| Revenue | $559M | $549M | $9.8M | +2% |
| Gross profit | $340M | $329M | $10.9M | +3% |
| Cost of revenue | $219M | $220M | −$1.1M | -0.5% |
| Operating profit | $3.4M | −$558M | $562M | — |
| Operating expenses | $336M | $887M | −$551M | -62% |
| Pre-tax earnings | $1.7M | −$567M | $569M | — |
| Research & development | $31.3M | $29.7M | $1.5M | +5% |
| SG&A | $259M | $264M | −$4.2M | -2% |
| Other operating costs | $45.8M | $594M | −$548M | -92% |
| Income tax benefit | $1.7M | −$4.0M | $5.7M | — |
| Net earnings | $3.4M | −$571M | $574M | — |
| Operating cash sources | $84.7M | −$488M | $572M | — |
| Depreciation & amortization | $73.5M | $74.4M | −$877K | -1% |
| Share-based compensation | $7.8M | $8.7M | −$982K | -11% |
| Working capital & other | $13.2M | −$570M | $584M | — |
| Operating cash flow | $71.5M | $82.6M | −$11.1M | -13% |
| Free cash flow (OCF − capex) | $35.0M | $29.1M | $5.9M | +20% |
| Capital expenditures | $36.5M | $53.5M | −$17.0M | -32% |
Questions
How much did Enovis's revenue grow year over year in Q3 2026?
Enovis's revenue rose $9.8M (+2%) from $549M in Q3 2025 to $559M in Q3 2026.
What drove Enovis's revenue change in Q3 2026?
Reconstructive +$15.4M (+6%); Prevention & Recovery −$5.5M (-2%).